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Infection with certain bacteria, parasites, and viruses alters the host immune system
to Leishmania major influencing disease outcome. Here, we determined the outcome
of a chronic infection with Trypanosoma brucei brucei on cutaneous leishmaniasis (CL)
caused by L. major. C57BL/6 mice infected with T. b. brucei were given a sub-curative
treatment with diminazene aceturate then coinfected with L. major by vector bites. Our
results revealed that infection with T. b. brucei controls CL pathology. Compared to
controls, coinfected mice showed a significant decrease in lesion size (P < 0.05) up
to 6 weeks post-infection and a significant decrease in parasite burden (P < 0.0001) at 3
weeks post-infection. Protection against L. major resulted from a non-specific activation
of T cells by trypanosomes. This induced a strong immune response characterized by
IFN-γ production at the site of bites and systemically, creating a hostile inflammatory
environment for L. major parasites and conferring protection from CL.
Keywords: Leishmania major, Trypanosoma brucei, coinfection, inflammation, cellular immunity, humoral
immunity, cutaneous leishmaniasis, protection
INTRODUCTION
Cutaneous leishmaniasis (CL) is an infectious disease caused by Leishmania parasites. CL affects
man and other mammals, causing ulcers in the skin and mucous membranes. With a million
cases registered worldwide in the last 5 years, CL is considered as a serious public health problem
concentrated in poor regions of the world (1). Leishmania parasites are transmitted by the bite of
vector sand flies together with vector-derived factors as part of a virulent infectious inoculum (2–4).
Protective adaptive immunity to CL depends on the induction of specific Th1-polarized CD4+T
cells that produce pro-inflammatory cytokines such as IL-12, IFN-γ, and TNF-α, responsible for
macrophage activation and parasite killing (5). In contrast, a Th-2 polarized immune response with
T cells producing cytokines such as IL-13, IL-4, IL-10, and IL-5 are associated to susceptibility to
Leishmania and an increase in the size and severity of L. major lesions (5).
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Humans and animals are exposed to different species of
fungi, bacteria, viruses, and parasites throughout their lifetime
where the risk of co-infections is likely. Coinfections with
Leishmania parasites and various pathogens have been reported
for both humans and animals (6–12). Experimentally, studies
have shown varying effects of co-infections on the progression
of leishmaniasis. Mice infected with Listeria monocytogenes
and later coinfected with L. major exhibited an enhanced
inflammatory response and developed larger lesions compared
to animals infected with L. major alone with no effect on
parasite loads (13). Similarly, mice infected with Lymphocytic
Choriomeningitis virus and subsequently coinfected with L.
major also presented bigger lesions associated with a decrease
in IFN-γ production. Coinfection with Schistosoma mansoni and
L. major demonstrated that the former delays the resolution of
CL in mice by decreasing the production of IFN-γ, TNF-α, and
NO, and increasing IL-4 levels (14). These reports point to the
importance of coinfections in modulating the outcome of CL.
Here, we demonstrate the protective effect of a chronic drug-
controlled infection with Trypanosoma b. brucei on L. major
infection. We show that T. b. brucei parasites create a non-
specific intense pro-inflammatory response, local, and systemic,
characterized by high levels of IFN-γ that creates an adverse
environment for Leishmania parasites.
MATERIALS AND METHODS
Animals and Ethics Statement
C57BL/6 mice were purchased from Charles River Laboratories
(Wilmington, MA) and were housed under pathogen-free
conditions at the NIAID Twinbrook animal facility in Rockville,
Maryland. Animal experimental procedures were reviewed and
approved by the Care and Use Committee of the National
Institute of Allergy and Infectious Diseases under animal
protocol LMVR4E. The Animal Care and Use program at NIAID
DIR complies with the Guide for the Care and Use of Laboratory
Animals and with the NIH OACU and ARAC guidelines.
Infection of Mice With T. b. brucei
Trypanosoma brucei brucei (Antat 1.1) blood form parasites
originally obtained from the Laboratory for Cellular and
Molecular Immunology, Vrije Universiteit Brussel, Pleinlaan
2, 1050 Brussels, Belgium, were passaged at the laboratory
of Professor S. Black, Department of Veretrinary and Animal
Sciences, UMASS Amherst. Parasites were provided as frozen
blood stabilates and were maintained at −70◦C. T. b. brucei
parasites were thawed and suspended in one ml of RPMI (Sigma-
Aldrich) and counted in a Neubauer chamber. For infection
of mice, 100 µL containing 5,000 T. b. brucei were injected
intraperitoneally. Soluble VSG of T. b. bruceiAnTat was prepared
as described earlier (15). Throughout the study, two experimental
groups were compared, mice infected with T. b. brucei then
co-infected with L. major and mice infected only with L. major.
Treatment of Mice With Diminazene
Aceturate
Mice infected with T. b. brucei were treated twice at 10-day
intervals with a subcurative dose of 40 mg/kg of diminazene
aceturate (Berenil, Sigma-Aldrich) in 100 µL of Phosphate
Buffered Saline (PBS) to control the number of systemic T. b.
brucei parasites prior to natural transmission of L. major (16).
The number of trypanosomes circulating in the blood were
monitored at 4, 18, and 51 days after infection. Blood (2.5 µl)
was collected by tail bleeds and diluted in 500 µL of phosphate-
buffered saline (PBS) for counting.
Sand Fly Infection and Transmission of
L. major to T. b. brucei Infected Mice
Lutzomyia longipalpis sand flies, Jacobina strain, were obtained
from a colony maintained at the Laboratory of Malaria
and Vector Research, NIAID, NIH. Frozen amastigotes of
Leishmania major (WR 2885) were thawed and washed, and
viable amastigotes were counted in a Neubauer chamber.
Artificial infection of Lu. longipalpis with 5 × 106 L. major
amastigotes/ml of defibrinated rabbit blood was performed as
described previously (17). Eight to ten days after infection, 10
sand flies were placed in a meshed vial that was applied to
a mouse ear for 2 h in the dark using custom-made clamps.
Transmission of L. major by bites of infected sand flies was
performed on day 30 after infection with T. b. brucei and 10 days
after the second treatment with diminazene aceturate.
Measurement of L. major Lesion Size
The diameter(s) and thickness(s) of the developing L. major
lesions were measured at 2, 4, and 6 weeks after exposure
to infected Lu. longipalpis sand flies using a Vernier caliper
(Mitutoyo, Baltimore, MD). The sum of the area of the
developing lesions was used to assess disease progression.
Elisa
IgG titers against L. major were measured using L. major
cell lysate antigen (Leish). ELISA plates (Immulon4-Thermo,
Waltham,MA)were coated overnight 4◦Cwith 20µg of Leish/ml
bicarbonate carbonate buffer pH 9.6. After washing and blocking
with 4%BSA for 2 h/37◦C, 50µL of serum (1:100) were incubated
for 1 h at 37◦C. After washing, plates were incubated with
alkaline phosphatase–conjugated anti-mouse IgG (1/1000, BD
Biosciences). The reaction was revealed using alkaline phosphate
substrate (Promega) and absorbance was read at 405 nm.
Briefly, to measure antibodies against T. b. brucei or Brugia
malayi wells were coated overnight with 10 µg of either T. b.
bruceiAnTat 1.1 (cell lysate) or AnTat 1.1 sVSG (a purified surface
membrane protein), or 10 µg of Brugia malayi microfilariae
cell lysate. After washing and blocking, mice sera (1:50) were
incubated for 2 h at 37◦C. After washing, plates were incubated
with alkaline phosphatase–conjugated anti-mouse IgG (1/1000,
BD Biosciences). The reaction was revealed using alkaline
phosphate substrate (Promega). Absorbance was read at 405 nm.
L. major Load by Limiting Dilution Assay
(LDA)
The lymph node draining the infected ear was macerated and
homogenized in 200 µl Schneider’s (Gibco, NY) supplemented
with 10% heat inactivated fetal bovine serum (Gibco, NY),
2mM L-glutamine,100 U/ml Penicillin and 100/ml Streptomycin
(complete Schneider medium). The macerate was serially diluted
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(1:2) in 96-well flat bottom microtiter plates containing 50ml
biphasic medium prepared using NNN medium with 10%
of defibrinated rabbit blood overlaid with 200 µl complete
Schneider medium. The plates were incubated at 27◦C and
examined up to 10 days after culture. The number of live L. major
promastigotes was determined from the highest dilution at which
L. major could be grown.
Evaluation of Brain Histopathology in T. b.
brucei-Infected Mice
Each brain section was fixed in 10% neutral buffered formalin
for 24 h, processed and sectioned (5mm), and stained with
hematoxylin-eosin (Histoserv, Germantown, MD). Slides
were evaluated by a board-certified veterinary pathologist
and photomicrographs were taken using the Olympus BX51
microscope and Olympus DP73 camera.
In vitro Stimulation of Spleen Cells With L.
major Cell Lysate (Leish)
Spleens were pooled by group from 5 to 7 mice for flow
cytometry. The spleens were macerated and treated with
ACK Lysis buffer (Lyfe technologies, USA) for 5min to lyse
erythrocytes. After washing, 5 × 106 splenic cells/mL were
cultured in RPMI medium (Life Technologies) supplemented
with 10% heat-inactivated fetal bovine serum, 100 U/ml of
penicillin, 100 mg/ml of streptomycin (Sigma, St. Louis, MO) in
the presence of 50µg/ml of Leish. Cells were incubated at 37◦C
with 5% CO2 for 24 h.
Flow Cytometry
Non-specific binding sites on viable splenic cells were blocked for
10min at 4◦C, using anti-CD16/32 FcγR antibody (BD). After
washing, the cells were incubated with a Life/Dead stain (Life
Technologies) for 20min to exclude dead cells from the analysis.
T cells and cytokines were identified using the following anti-
mouse antibodies: PerCP- labeled anti-CD4, APC-Cy7 labeled
anti-TCR-β, APC labeled anti-IFN-γ, and Pacific Blue labeled
anti-IL10. For B cell staining the following anti-mouse antibodies
were used: PE labeled anti-CD138 and APC labeled anti-B220.
Incubation with all antibodies were conducted for 30min at 4◦C.
All samples were acquired using a MACSQuant (Miltenyi Biotec)
and data were analyzed with the FlowJo V10 software package.
RNA Extraction and cDNA Synthesis
Total RNA was isolated from the ear of each mouse using the
Ambion Kit (Life Technologies) according to the manufacturer’s
instructions. cDNA was obtained using 100 µg RNA from
individual mice ears that was synthetized with 4 µL de qScript
cDNA (SuperMix Superscript III, Invitrogen) following the
manufacturer’s instructions. The cDNAs were stored at −20◦C
until cytokine analysis by Real time PCR.
Real Time PCR for Cytokine Quantification
PCR was carried out using the Perfect Master mix (Roche
Diagnostics) and gene specific primer sets for IFN-γ, TNF-
α, IL-10, IL-12, and IL-4 using the Light Cycler 480 (Roche
Diagnostics). A standard curve for each set of primers was
generated as recommended by the manufacturer. The expression
levels of the genes of interest were normalized to RNA levels of
GAPDH, an endogenous gene. The results are expressed in fold
change over gene expression in the control group.
Statistical Analysis
Graphs and statistical significance were prepared and analyzed
using GraphPad Prism Software 7.0. An unpaired t-test followed
byMann-Whitney test or a one-way ANOVA followed by Tukey’s
multiple comparisons test were used to evaluate statistical
significance among groups. A p value < 0.05 was considered
statistically significant.
RESULTS
A Treatment Regimen With Diminazene
Aceturate Produces a Chronic Infection
With T. b. brucei
Treatment of mice with two doses of 40 mg/kg diminazene
aceturate at 10-day intervals after the intraperitoneal injection
of 5,000 T. b. brucei (Figure 1A) maintained a chronic drug-
controlled infection with T. b. brucei (Figure 1B). We chose
three timepoints to assess the number of circulating blood
trypanosomes: Four days, before the first drug treatment; 18
days, before the second drug treatment; and 51 days, at the
first evaluation after L. major infection. Counts of T. b. brucei
circulating in the blood demonstrated the growth of parasites
on day four, prior to drug treatment. On day 18, two days
before the second drug treatment, the number of T. b. brucei
parasites declined to sub-detectable levels in blood indicating
their transient clearance from circulation (Figure 1B). The
persistence of T. b. brucei parasites in co-infected mice after
the second drug treatment was confirmed by their recovery to
pre-drug treatment levels on day 51, three weeks after L. major
infection (Figure 1B).
To investigate the consequence of the persistence of T. b.
brucei after treatment with two doses of 40mg/kg diminazene
aceturate, histopathologic analyses of the brain of mice was
conducted 10 days after T. b. brucei infection, and three and 6
weeks after transmission of L. major to mice (Figure 1C). Ten
days after infection with 5,000 T. b. brucei and prior to the first
dose of drug, the brains from infected and naive mice, the latter
representing a steady state baseline, were similar and unaltered
(Figure 1C, I and II). In comparison, three weeks after infection
with L. major (51 days after infection with T. b. brucei and 31
days after administration of the second drug dose), the brains
of coinfected mice demonstrated acute meningoencephalitis that
was absent from mice infected with L. major alone (Figure 1C,
III and IV). The meningoencephalitis in brains of coinfected
mice was characterized by an intense neutrophilic infiltrate
within the meninges, extending at a lesser degree to different
regions of the neuroparenchyma (Figure 1C, IV). Importantly,
we observed a few T. b. brucei parasites in the choroid plexus
of the third ventricle, indicating that the blood/brain barrier
has been crossed. At six weeks after infection with L. major (72
days after infection T. b. brucei and 52 days after administration
Frontiers in Immunology | www.frontiersin.org 3 December 2018 | Volume 9 | Article 2855
Pereira et al. Trypanosoma brucei and Leishmania major Coinfection
FIGURE 1 | A model for a drug-controlled chronic infection with T. b. brucei. (A) A schematic representation of the experimental study design. Drug, diminazene
aceturate. (B) T. b. brucei parasite load per ml of blood in mice before the first and second drug treatments (days 4 and 18, respectively), and 3 weeks after exposure
to 10 sand flies infected with L. major (day 51). Data are representative of three independent experiments (n = 8–13 mice). (C,D) Brain sections of mice stained with
hematoxylin and eosin. (C) naive (I) and 10 days after infection with T. b. brucei (II), and 3 or 6 weeks after infection with L. major in the absence (III, V) or presence of
T. b. brucei (IV, VI), respectively. Arrows highlight areas of inflammation. Scale, 50µm. (D) Magnification of the choroid plexus (lower panel) within the dorsal third
ventricle of the brain (upper panel) 6 weeks after infection with L. major in the presence of T. b. brucei. Dashed boxes highlight areas with T. b. brucei parasites. Scale,
100µm). Pictures are representative of two independent experiments (n = 5 mice/group).
of the second drug dose) the brains of mice infected with L.
major alone were unchanged while the brain tissue of coinfected
mice showed a more chronic meningoencephalitis that was
composed largely of lymphocytes and plasma cells (Figure 1C,
V and VI). Additionally, more T. b. brucei parasites were evident
(Figure 1D, Dashed boxes) within the choroid plexus of the third
ventricle (Figure 1D) which also displayed a large number of
plasma cells. Of note, mice coinfected with T. b. brucei and L.
major also exhibited a lower rate of weight gain beyond the
second week after L. major transmission compared to animals
infected with L. major alone (Supplementary Figure 1).
T. b. brucei Infection Results in a Sustained
Control of Leishmania major Lesion
Pathology Following Vector-Transmission
To determine the influence of a T. b. brucei infection on the
development of CL, mice infected or not with T. b. brucei were
challenged 10 days after the second dose of diminazene aceturate
with 10 L. major-infected Lu. longipalpis sand flies harboring
mature infections with a geometric mean parasite load of 104 and
an average of 60% infectious metacyclics per midgut (Figure 2A).
After transmission, we followed the course of developing ulcers
bymeasuring the lesion(s) area inmice ears. Mice coinfected with
T. b. brucei and L. major developed significantly smaller lesions
(P < 0.05) up to 6 weeks post infection with L. major (Figure 2B)
and did not manifest open ulcers (Figure 2B, pictures) compared
to control mice infected with L. major alone. Interestingly, a
significant reduction in Leishmania parasite ear burden was
observed in coinfected compared to controls at 3 weeks post-
infection, however, by 6 weeks the parasite number in coinfected
mice recovered in the absence of pathology and were comparable
in number in both groups (Figure 2C).
T. b. brucei Infection Induces Expansion of
the Splenic Plasma B Cell Compartment
To investigate whether the reduced L. major pathology in
coinfected mice is associated to cross-reactive immunity directed
against similar trypanosomatid antigens, we tested the serum
from mice infected with L. major in the presence or absence
of T. b. brucei against the cell lysate or soluble VSG protein
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FIGURE 2 | A chronic infection with T. b. brucei controls L. major lesion pathology. (A) The parasite burden and percent metacyclics in Lu. longipalpis sand flies at the
time of L. major vector-transmission to mice. (B,C) Mice infected with L. major by vector challenge in the absence (L. major) or presence (Coinfection) of a preceding
infection with T. b. brucei. (B) Area of L. major ear lesions. Pictures show the pathology of cutaneous lesions at 4 weeks after L. major infection. C, L. major parasite
load at 3 and 6 weeks after infection. *P < 0.05; ****P < 0.0001; Unpaired two-tailed t-test. Data are representative of three independent experiments (n = 8–13 mice).
from the trypanosomes. Animals infected with L. major alone
had no cross-reactive antibodies to either anti-AnTat 1.1 Lysate
or VSG (Figure 3A), suggestive of the absence of shared
antigens. Conversely, mice coinfected with both T. b. brucei
and L. major reacted to both antigens (P < 0.0001, Figure 3A).
Counterintuitively, 10 days after infection with T. b. brucei, and
before infection with L. major, mice showed significantly higher
IgG titers against L. major cell lysate (Figure 3A, P < 0.0001) as
well as the cell lysate from an unrelated parasite, Brugia malayi
microfilaria (Figure 3A, P < 0.01), compared to naive mice
indicative of polyclonal activation of B cells in trypanosome-
infected mice. Of note, a further increase in the IgG titer against
L. major cell lysate was observed three weeks after coinfection
with L. major (Figure 3A).
To assess the activation state of B cells in T. b. brucei
infected mice, a plasma cell specific B220+/CD138+ staining
was performed on spleen cells. Ten days following infection
with T. b. brucei, there was a seven-fold increase in plasma
B cells compared to the basal state of naive mice (Figure 3B).
Moreover, at 3 and 6 weeks after transmission with L. major-
infected sand flies a 3- and 28-fold expansion of plasma cells was
observed in coinfected mice compared to animals infected with
L. major alone (Figure 3C), likely due to the increasing number
of trypanosomes in circulation.
T. b. brucei Infection Produces an
Inflammatory Environment at the Site of L.
major-Infected Vector Bites and
Systemically
To understand the basis of the protection from L. major
conferred by an active infection with T. b. brucei, we investigated
the ex vivo expression of cytokines in mice ears 3 and 6 weeks
after exposure to infected sand fly bites. Three weeks after the
bites of L. major-infected sand flies, the ears of mice that were
also infected with T. b. brucei showed a significant increase in
the local expression of the pro-inflammatory cytokines IFN-γ
(P < 0.01) and TNF-α (P < 0.001) when compared to mice
infected with L. major alone (Figure 4A). Importantly, six weeks
after L. major infection, the expression of both pro- and anti-
inflammatory cytokines was significantly enhanced (P < 0.01) in
coinfected compared to controls though the local milieu was still
dominated by IFN-γ (Figure 4A). This indicates that T. b. brucei
induces a cell-mediated as well as a humoral hyper-inflammatory
environment.
The induction of a cellular hyper-inflammatory environment
after infection with T. b. bruceiwas systemic. At three weeks post-
infection with L. major, the number of IFN-γ-producing, and
to a lesser extent IL-10-producing, TCRß+CD4+ splenic T cells
(Supplementary Figure 2) was higher in mice coinfected with T.
b. brucei compared to mice only infected with L. major, with or
without stimulation with L. major cell lysate (Leish), emphasizing
the pro-inflammatory nature of the response (Figure 4B).
TCRß+CD4− splenic T cells (Supplementary Figure 2), that
include CD8+ T cells, of mice coinfected with L. major and
T. b. brucei also produced higher levels of IFN-γ and IL-10
compared to mice only infected with L. major, but consisted
mainly of IL-10-producing cells (Figure 4B). Interestingly, in
the absence of antigen stimulation, the number of CD4+ and
CD4− T cells producing IFN-γ were about 4-fold higher in co-
infected compared to L. major-infected mice, and were about
2-fold higher after stimulation with Leish.
DISCUSSION
Coinfections in humans are more the norm than the exception,
particularly in developing countries where infectious diseases
are prevalent (18–20). For Leishmania parasites, coinfection
with HIV is the best characterized. HIV enhances susceptibility
to Leishmania reinfection and relapse, increases lethality of
VL, and influences disease prevalence worldwide threatening
control and elimination efforts [www.who.int/leishmaniasis/
burden/hiv_coinfection/burden_hiv_coinfection/en/; (21–24)].
Experimentally, several models of coinfection with Leishmania
also resulted in disease enhancement (13, 14). Here, we
demonstrate that infection of mice with T. b. brucei has a
protective effect on L. major infection despite a virulent challenge
via infected sand fly bites. Using amousemodel of coinfection, we
show that an infection with T. b. brucei affects both the humoral
and cellular arms of the host immune system generating a non-
specific polyclonal activated state. This creates an inflammatory
environment dominated by high levels of IFN-γ that adversely
affects the invading Leishmania parasites. Moreover, this T. b.
brucei-induced hyperinflammatory state was observed locally
in the skin at bite sites and systemically, suggesting that its
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FIGURE 3 | The humoral immune response in mice coinfected with T. b. brucei and L. major. Mice serum and spleen cells were collected from naive animals, 10 days
after infection with T. b. brucei, and 3 and 6 weeks after infection with L. major. (A) Total IgG levels against T. b. brucei AnTat 1.1 cell lysate, T. b. brucei AnTat 1.1
soluble VSG, L. major cell lysate, or B. malayi microfilaria cell lysate. (B) The frequency of splenic B220+/CD138+ plasma cells before and 10 days after infection with
T. b. brucei. Cell frequency is indicated on the upper left corner of dot plots. (C) The absolute number of plasma cells in pooled spleens of mice at 3 and 6 weeks
following challenge with L. major-infected sand flies. T. b. brucei, infection with T. b. brucei alone; L. major, infection with L. major alone; Coinfection, infection with L.
major following a preceding infection with T. b. brucei. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, one-way ANOVA followed by Tukey’s multiple
comparisons test. Representative data from 2 to 3 independent experiments are shown. (A, n = 10–17 mice; B,C, n = 5–7 mice).
protective effect may influence both visceral as well as cutaneous
leishmaniasis.
Though we observed the well-established severe effect of
T. brucei on the B cell compartment, with infection inducing
non-specific polyclonal B cell activation with production of
nonspecific antibodies, B cell apoptosis, and loss of memory B
cells (25, 26), it is well established that the humoral response
is of little importance in protective immunity to L. major (27,
28). Instead, protection is mainly conferred by IFN-γ-producing
CD4T cells (5, 29). Excessive production of cytokines is a
hallmark of African trypanosome infections (30–32). Moreover,
IFN-γ production by variant surface glycoprotein-specific CD4T
cells has been known to be important for both control of
(early stages), and susceptibility to (late stages), infection with
African trypanosomiasis (31, 32). Here, mice coinfected with
T. b. brucei and L. major exhibited a strong inflammatory
response in L. major-infected mice ears that was dominated
by high levels of IFN-γ. Though other cells such as NK cells
could have contributed to the large amounts of IFN-γ produced
in the skin, the robust IFN-γ response of CD4T cells in the
spleen indicates that this cell population is likely a major
contributor to the proinflmmaotry environment in the ear 3
weeks post infection with L. major. This inflammatory response
was sustained throughout the study timeline andwas significantly
higher compared tomice infected with L. major alone elucidating
the mechanism underlying protection against CL pathology in
trypanosome-infected mice. Moreover, TCRß+CD4− splenic T
cells, that include CD8+ T cells, also participated to a lesser
extent in the inflammatory response caused by T. b. brucei
supporting previous findings in a T. b. brucei AnTat 1.1/C57BL6
mice model of infection where CD8T cells were implicated in
IFN-γ production (32).
In mice, infection with T. brucei species can be cured if
diminazene aceturate is given early, within 3–7 days after
infection (33). However, if given later or at suboptimal drug
doses, trypanosomes can infect and proliferate in the brain
where they are protected by the blood brain barrier from
the effect of drugs, becoming a permanent source of relapse
(16, 33). In this study, two doses of 40 mg/kg of diminazene
aceturate given at 10 and 20 days after injection with 5,000
T. b. brucei AnTat 1.1 resulted in a chronic drug-controlled
infection with brain inflammation observed at 51 and 71 days
post-trypanosome infection. As such, this model can be adapted
for the study of chronic trypanosome infections. A similar model
using a drug regimen with Moranyl has been successfully used
to establish a chronic T. b. brucei AnTat 1.1 infection where mice
developmeningoencephalitis (34). Developing chronic models of
ongoing trypanosome infections would be useful for the study of
coinfections requiring extended study time lines.
Both leishmaniasis and Human African trypanosomiasis
(HAT) are vector-borne diseases transmitted by sand flies and
tsetse flies, respectively (35, 36). Generally, climate change,
conflict and globalization have promoted the spread of vector-
borne diseases (1, 37). For leishmaniasis and HAT, models have
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FIGURE 4 | The cellular inflammatory response in mice after infection with L. major in the presence of absence of T. b. brucei. Mice infected or not with T. b. brucei
were exposed to 10 L. major-infected Lu. longipalpis sand flies. (A) The local inflammatory response in mice ears at 3 and 6 weeks after infection with L. major. mRNA
expression relative to naive mice ears was determined for IFN-γ, TNF-α, IL-12, IL-4, and IL-10 by RT-PCR. Cumulative data from 2 independent experiments are
shown (n = 8–15 mice). Bars denote the mean ± 1SD. T. b. brucei, infection with T. b. brucei alone; L. major, infection with L. major alone; Coinfection, infection with
L. major after a preceding infection with T. b. brucei. **P < 0.01; ***P < 0.001; ****P < 0.0001, unpaired two-tailed t-test. (B) The number of CD4+ and CD4− T cells
producing IFN-γ or IL-10 from mice spleens three weeks after vector-transmission of L. major to mice infected or not with T. b. brucei. Pooled spleen cells were left
unstimulated (Media) or were stimulated with L. major cell lysate (Leish). Representative data from 2 independent experiments are shown (n = 8 mice).
predicted expansion of their vector ranges due to climate change
(37, 38). Combined with continued conflict and population
displacement, this will likely increase the areas where both
diseases co-exist increasing the chances of coinfections. At
present, leishmaniasis is more broadly distributed while HAT
remains restricted to sub-Saharan Africa (39, 40). Interestingly,
despite regions where both diseases are endemic, most notably
South Sudan where a high number of both T. b. gambiense
HAT and VL cases have been reported (39, 41), to our
knowledge there have been no documented human cases of
HAT/VL coinfections. Potentially, HAT infected individuals may
be resistant to leishmaniasis.
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